drug-eluting stents

Novedades en las guías de prevención primaria de la AHA/ACC

LpA: 30-Year Cardiovascular Followup in Primary Prevention Cohorts

For years, treating dyslipidemia mainly focused on reducing LDL cholesterol (LDL-C) with statins, which had shown benefits in reducing atherosclerotic cardiovascular disease (ASCVD). Lipoprotein(a) [Lp(a)] is a form of apoB-containing lipoprotein bound to a hydrophilic, highly glycosylated protein called apolipoprotein(a) [apo(a)]. Circulating levels of Lp(a) are genetically determined, and are hardly affected by eating habits<a href="https://solaci.org/en/2024/04/30/lpa-30-year-cardiovascular-followup-in-primary-prevention-cohorts/" title="Read more" >...</a>

Outcomes of the Use of Drug Coated Balloons in the Treatment of De Novo Coronary Lesions

Drug coated balloon (DCB) angioplasty offers a novel strategy for treating coronary artery disease. Studies assessing this strategy have shown clinical outcomes comparable to drug-eluting stents’ (DES) in patients with in-stent restenosis and&nbsp;de novo&nbsp;disease in small vessels. However, evidence for the use of DCB in large coronary vessels is limited. This observational, retrospective study DCB<a href="https://solaci.org/en/2023/12/21/outcomes-of-the-use-of-drug-coated-balloons-in-the-treatment-of-de-novo-coronary-lesions/" title="Read more" >...</a>

Dietas bajas en carbohidratos y progresión de la calcificación coronaria

Calcified Nodules and the Importance of OCT Categorization prior PCI

TLR associated factors in patients with calcified nodules.&nbsp; Patients with complex cardiomyopathies undergoing percutaneous coronary intervention are increasingly common, as is the case for calcified lesions and calcified nodules (CN).&nbsp; Procedure complexity not only involves planning, but also establishing patient prognosis, taking into consideration the fact that most target vessel events occur at long term<a href="https://solaci.org/en/2023/06/24/calcified-nodules-and-the-importance-of-oct-categorization-prior-pci/" title="Read more" >...</a>

¿Debemos utilizar balones liberadores de droga en pacientes con enfermedad de múltiples vasos?

Comparative Study of Two Drug Coated Balloons: Angiographic and Clinical Outcomes

The incidence of in-stent restenosis (ISR) requiring repeat revascularization ranges between 5% and 10% of PCI patients receiving new generation drug eluting stents (DES). This is why the current European guidelines on myocardial revascularization recommend treating ISR with drug coated balloons (DCB) with class I recommendation, level of evidence A. DCB are mostly coated with<a href="https://solaci.org/en/2023/04/21/comparative-study-of-two-drug-coated-balloons-angiographic-and-clinical-outcomes/" title="Read more" >...</a>

DES de 2.0 mm para vasos muy pequeños: ¿Es viable?

ISAR Score: Can We Predict the Need for Repeat PCI in DES Restenosis?

Score to predict the risk of repeat PCI in DES restenosis. With the use of drug eluting stents (DES) instent restenosis (ISR) has seen a significant reduction vs. bare metal stents (BMS) restenosis.&nbsp; The main cause of DES failure is ISR. This entity is difficult to manage because of its high recurrence and reintervention risk.<a href="https://solaci.org/en/2023/04/12/isar-score-can-we-predict-the-need-for-repeat-pci-in-des-restenosis/" title="Read more" >...</a>

¿Debemos utilizar balones liberadores de droga en pacientes con enfermedad de múltiples vasos?

Should We Use Drug Coated Balloons in Patients with Multivessel Disease?

Recent studies have shown that a drug coated balloons (DCB) based approach resulted non inferior when compared against drug eluting stents (DES) only approach in patients with instent restenosis and de novo lesions in small vessel disease. So far, two international consensuses have reported the use of DCB is feasible and safe to treat native<a href="https://solaci.org/en/2023/02/22/should-we-use-drug-coated-balloons-in-patients-with-multivessel-disease/" title="Read more" >...</a>

¿Cuál es la mejor antiagregación en la angioplastia primaria a 12 meses?

Monotherapy with P2Y12 in Complex Interventions: Less and Less Risky

&nbsp;Monotherapy in patients with complex angioplasty: meta-analysis of 5 randomized studies.&nbsp; Even though prolonged dual antiplatelet therapy (DAPT) might reduce the risk of important ischemic complications, this reduction will come at the expense of a significant increase of bleeding risk, which makes us reassess the cost benefit ratio of this decision. This is also why<a href="https://solaci.org/en/2023/02/10/monotherapy-with-p2y12-in-complex-interventions-less-and-less-risky/" title="Read more" >...</a>

¿Debemos comenzar a utilizar IVUS en las CTO?

What Is the Best Strategy for Moderately Complex Femoropopliteal Lesions?

At present, PCI is the preferred treatment for femoropopliteal lesions and drug coated balloons (DCB) have shown good performance. However, they have not yet been shown superior to bare-metal stents (BMS).&nbsp; This study compared randomized trials IN.PACT SFA I/II and IN.PACT JAPAN including 288 patients vs. the prospective Complete SE and DURABILITY II with 483<a href="https://solaci.org/en/2023/01/31/what-is-the-best-strategy-for-moderately-complex-femoropopliteal-lesions/" title="Read more" >...</a>

The Most Important Articles of 2022 in Peripheral Vascular Disease

Discover the most important scientific articles of 2022 in peripheral vascular disease in our website. EMINENT Trial | Stent Eluvia vs BMS in Femoropopliteal Territory Endovascular therapy in femoropopliteal territory has become the standard, mainly with self-expanding stents, aimed at preventing early vascular recoil and late constrictive remodeling.&nbsp; Thromboendarterectomy vs. Endovascular Therapy in Common Femoropopliteal<a href="https://solaci.org/en/2023/01/19/the-most-important-articles-of-2022-in-peripheral-vascular-disease/" title="Read more" >...</a>

ELUVIA: DES en territorio femoropoplíteo con lesiones complejas

EMINENT Trial | Stent Eluvia vs BMS in Femoropopliteal Territory

Endovascular therapy in femoropopliteal territory has become the standard, mainly with self-expanding stents, aimed at preventing early vascular recoil and late constrictive remodeling.&nbsp; Randomized studies have shown that the use of Paclitaxel drug eluting stents (DES) reduces the number of new revascularizations (even though these studies compared mostly against conventional balloons, which is why we<a href="https://solaci.org/en/2022/10/26/eminent-trial-stent-eluvia-vs-bms-in-femoropopliteal-territory/" title="Read more" >...</a>

Top